RETROSPECTIVE REVIEW OF THE EFFICACY OF TOPICAL BROMFENAC (0.09%) AS AN ADJUNCTIVE THERAPY FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION-Reference-Cited by-同舟云学术

RETROSPECTIVE REVIEW OF THE EFFICACY OF TOPICAL BROMFENAC (0.09%) AS AN ADJUNCTIVE THERAPY FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Published:2009-11 Issue:10 Volume:29 Page:1527-1531
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

ZWEIFEL SANDRINE A.,ENGELBERT MICHAEL,KHAN SAMIRA,FREUND K BAILEY

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference20 articles.

1. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.;Brown;N Engl J Med,2006

2. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study.;Brown;Ophthalmology,2009

3. Rationale for combination therapies for choroidal neovascularization.;Spaide;Am J Ophthalmol,2006

4. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.;Jonas;Acta Ophthalmol Scand,2005

5. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.;Spaide;Ophthalmology,2005

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis;BMC Ophthalmology;2024-08-23

2. Age-associated macular degeneration: Epidemiologic features, complications, and potential therapeutic approaches;Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases;2024

3. Effects of systemic drugs on the development and progression of age-related macular degeneration;Survey of Ophthalmology;2023-05

4. Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema;International Ophthalmology;2023-04-21

5. Evaluation of Using Topical Bromfenac as an Adjunctive Treatment with Intravitreal Ranibizumab for Diabetic Macular Edema;2023-02-08